T
Tim Horn
Researcher at Treatment Action Group
Publications - 20
Citations - 1230
Tim Horn is an academic researcher from Treatment Action Group. The author has contributed to research in topics: Pre-exposure prophylaxis & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 7, co-authored 16 publications receiving 1069 citations.
Papers
More filters
Journal ArticleDOI
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel.
Melanie A. Thompson,Michael J. Mugavero,K. Rivet Amico,Victoria A. Cargill,Larry W. Chang,Robert E. Gross,Catherine Orrell,Frederick L. Altice,David R. Bangsberg,John G. Bartlett,Curt G. Beckwith,Nadia Dowshen,Christopher M. Gordon,Tim Horn,Princy Kumar,James D. Scott,Michael J. Stirratt,Robert H. Remien,Jane M. Simoni,Jean B. Nachega +19 more
TL;DR: Recommendations cover ART strategies, adherence tools, education and counseling, and health system and service delivery interventions that cover specific issues pertaining to pregnant women, incarcerated individuals, homeless and marginally housed individuals, and children and adolescents, as well as substance use and mental health disorders.
Journal ArticleDOI
The State of Engagement in HIV Care in the United States: From Cascade to Continuum to Control
TL;DR: This review synthesizes the state of engagement in HIV care in the United States, focusing on research, practice, and policy considerations, and includes a look to the future in addressing the greatest challenge and opportunity facing the authors' domestic HIV epidemic.
Journal ArticleDOI
Towards an integrated primary and secondary HIV prevention continuum for the United States: a cyclical process model
TL;DR: Horn et al. as discussed by the authors presented a comprehensive, primary and secondary HIV prevention continuum model for the United States as a conceptual framework to identify key steps in reducing HIV incidence and improving health outcomes among those vulnerable to, as well as those living with, HIV infection.
Journal ArticleDOI
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
TL;DR: The improved safety of F/TAF is worth no more than an additional $370 per person per year in the presence of a generic F/TDF alternative, and the maximum permissible fair price for F/ TAF was $8970 per year.
Journal ArticleDOI
Insurance coverage and financing landscape for HIV treatment and prevention in the USA.
Jennifer Kates,Lindsey Dawson,Tim Horn,Amy Killelea,Nicole C McCann,Jeffrey S. Crowley,Rochelle P. Walensky +6 more
TL;DR: In 2010, the US health insurance system underwent one of its most substantial transformations with the passage of the Affordable Care Act, which increased coverage for millions of people in the USA, including those with and at risk of HIV as discussed by the authors.